Suppr超能文献

芦可替尼相关的结核病表现为颈部肿块。

Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump.

作者信息

Shamil Eamon, Cunningham David, Wong Billy L K, Jani Piyush

机构信息

ENT Department, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.

出版信息

Case Rep Infect Dis. 2015;2015:284168. doi: 10.1155/2015/284168. Epub 2015 Dec 15.

Abstract

Tuberculosis is an opportunistic infection with protean clinical manifestations. We describe a case of Ruxolitinib induced miliary tuberculosis presenting as a neck lump. A 78-year-old female presented with a two-month history of right-sided neck lump associated with fever, night sweats, and significant weight loss. She had a past medical history that included myelofibrosis, being treated with Ruxolitinib. Examination demonstrated 4 × 4 cm right-sided cervical lymphadenopathy. A chest radiograph showed extensive shadowing in both lungs. CT scan demonstrated perilymphatic nodes in addition to the cervical mass. An ultrasound-guided biopsy of a cervical lymph node demonstrated confirmed Mycobacterium tuberculosis infection. It was hypothesized that use of Ruxolitinib through its selective inhibition of Janus-activated kinases 1 and 2 resulted in immunosuppression and miliary tuberculosis in this patient. The medication was stopped and a 12-month regime of antituberculosis therapy commenced. She remained well at one-year follow-up with resolution of lung involvement. Clinicians should consider tuberculosis as a differential diagnosis for patients presenting with a neck lump, particularly in those taking immunosuppressant medication such as Ruxolitinib. A multidisciplinary approach is needed to promptly treat the tuberculosis and consider discontinuation of Ruxolitinib.

摘要

结核病是一种具有多种临床表现的机会性感染。我们描述了一例鲁索替尼诱发的粟粒性结核病,表现为颈部肿块。一名78岁女性,有两个月的右侧颈部肿块病史,伴有发热、盗汗和明显体重减轻。她既往有骨髓纤维化病史,正在接受鲁索替尼治疗。检查发现右侧颈部有4×4厘米的淋巴结肿大。胸部X光片显示双肺广泛阴影。CT扫描显示除颈部肿块外还有肺门淋巴结。颈部淋巴结的超声引导活检证实为结核分枝杆菌感染。据推测,该患者使用鲁索替尼通过选择性抑制Janus激活激酶1和2导致免疫抑制和粟粒性结核病。停用该药物并开始了为期12个月的抗结核治疗方案。在一年的随访中,她情况良好,肺部病变消退。临床医生应将结核病作为颈部肿块患者的鉴别诊断,特别是对于正在服用免疫抑制剂药物如鲁索替尼的患者。需要采取多学科方法来及时治疗结核病并考虑停用鲁索替尼。

相似文献

1
Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump.
Case Rep Infect Dis. 2015;2015:284168. doi: 10.1155/2015/284168. Epub 2015 Dec 15.
2
Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis.
J Infect Dev Ctries. 2018 Oct 31;12(10):926-928. doi: 10.3855/jidc.9993.
5
Erythema nodosum associated with reactivation tuberculous lymphadenitis (scrofula).
Int J Dermatol. 2002 Mar;41(3):173-5. doi: 10.1046/j.1365-4362.2002.01390.x.
6
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
Infect Drug Resist. 2020 Apr 8;13:1017-1021. doi: 10.2147/IDR.S249030. eCollection 2020.
8
Tuberculous pyelonephritis in children: three case reports.
Paediatr Int Child Health. 2017 Nov;37(4):292-297. doi: 10.1080/20469047.2017.1386847. Epub 2017 Nov 1.
9
[Lymph node tuberculosis as primary manifestation of Hodgkin's disease].
Med Klin (Munich). 2006 Jun 15;101(6):500-4. doi: 10.1007/s00063-006-1071-3.

引用本文的文献

3
Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review.
Infect Drug Resist. 2020 Sep 28;13:3309-3316. doi: 10.2147/IDR.S267997. eCollection 2020.
5
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
Infect Drug Resist. 2020 Apr 8;13:1017-1021. doi: 10.2147/IDR.S249030. eCollection 2020.
8
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.
Ther Clin Risk Manag. 2017 Feb 13;13:169-177. doi: 10.2147/TCRM.S121683. eCollection 2017.
9
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2016 Dec;14(12):1572-1611. doi: 10.6004/jnccn.2016.0169.
10
Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.
Case Rep Hematol. 2016;2016:2389038. doi: 10.1155/2016/2389038. Epub 2016 Oct 23.

本文引用的文献

1
Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
Leuk Lymphoma. 2015 May;56(5):1528-9. doi: 10.3109/10428194.2014.963082. Epub 2014 Nov 5.
2
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
Ann Hematol. 2015 Mar;94(3):519-20. doi: 10.1007/s00277-014-2183-0. Epub 2014 Aug 30.
3
Disseminated tuberculosis associated with ruxolitinib.
Leukemia. 2014 Aug;28(8):1750-1. doi: 10.1038/leu.2014.104. Epub 2014 Mar 13.
4
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Blood. 2013 Nov 28;122(23):3843-4. doi: 10.1182/blood-2013-10-531103.
6
Bilateral toxoplasmosis retinitis associated with ruxolitinib.
N Engl J Med. 2013 Aug 15;369(7):681-3. doi: 10.1056/NEJMc1302895.
7
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Chest. 2013 May;143(5):1478-1479. doi: 10.1378/chest.12-1604.
8
9
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
10
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验